Clinical Trial Update: Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial comparing PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) ophthalmic solution to GANFORT in open-angle glaucoma and ocular hypertension; study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• GANFORT ophthalmic solution (bimatoprost/timolol)
• PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) ophthalmic solution

Snippet

Sponsor: Aerie Pharmaceuticals | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2022-01-19